A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomas

Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells

(2016) Khin Thway et al.   BRITISH JOURNAL OF CANCER

Novel antibody probes for the characterization of endosialin/TEM-1

(2016) Daniel J. O’Shannessy et al.   Oncotarget

Histology-Driven Therapy

(2015) Jonathan Noujaim et al.   INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY

Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies

(2015) C. Rouleau et al.   MOLECULAR CANCER THERAPEUTICS

Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature

(2015) Katherine Rybinski et al.   Oncotarget

A First-in-Human Phase I Study of MORAb-004, a Monoclonal Antibody to Endosialin in Patients with Advanced Solid Tumors

(2014) L. A. Diaz et al.   CLINICAL CANCER RESEARCH

Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials

(2013) Scott M Berry et al.   Clinical Trials

Endosialin/TEM-1/CD248 regulates pericyte proliferation through PDGF receptor signaling

(2010) Brian Tomkowicz et al.   CANCER BIOLOGY & THERAPY

Endosialin Protein Expression and Therapeutic Target Potential in Human Solid Tumors: Sarcoma versus Carcinoma

(2008) C. Rouleau et al.   CLINICAL CANCER RESEARCH

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study

(2008) Martee L. Hensley et al.   GYNECOLOGIC ONCOLOGY

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial

(2008) Martee L. Hensley et al.   GYNECOLOGIC ONCOLOGY